Tavolimab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Tavolimab
Monoclonal antibody
Type ?
Source Chimeric/humanized hybrid (mouse/human)
Target CD134
Clinical data
Synonyms MEDI0562
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6508H10026N1730O2032S42
Molar mass 146.4 g/mol

Tavolimab (MEDI0562, formerly tavolixizumab) (INN[1]) is a chimeric/humanized monoclonal antibody designed for the treatment of cancer.

This drug is being developed by MedImmune.[2]

References[edit]